Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ:IRTC)

136.24 +0.48 (+0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about iRhythm Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Healthcare Stock on Our Buy List and 2 to Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
iRhythm (IRTC) Stock Trades Up, Here Is Why
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after the positive sentiment from Wall Street analysts who saw further potential in the... 
Via StockStory
Topics Artificial Intelligence
Patient Monitoring Stocks Q1 In Review: iRhythm (NASDAQ:IRTC) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
Earnings Scheduled For May 1, 2025
Via Benzinga
1 Growth Stock with Impressive Fundamentals and 2 to Be Wary Of
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
3 Small-Cap Stocks Facing Headwinds
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
Expert Outlook: iRhythm Technologies Through The Eyes Of 6 Analysts
Via Benzinga
3 Inflated Stocks in Hot Water
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Demystifying iRhythm Technologies: Insights From 6 Analyst Reviews
Via Benzinga
3 Overrated Stocks Facing Headwinds
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
IRTC Q1 Earnings Call: Outperformance Driven by Zio AT and Primary Care Channel Expansion
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 20.3% year on year to $158.7 million. The company’s... 
Via StockStory
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts
iRhythm raises 2025 sales forecast and launches Zio ECG system in Japan as analysts boost ratings and price targets on strong Q1 performance. 
Via Benzinga
Wells Fargo Upgrades iRhythm Technologies Stock, Raises Price Target To $130: Retail’s Thrilled
The firm’s new target on iRhythm implies a 19.7% upside to Thursday’s closing price. 
Via Stocktwits
This FTAI Aviation Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Via Benzinga
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Via Benzinga
Deep Dive Into iRhythm Technologies Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
iRhythm (NASDAQ:IRTC) Surprises With Strong Q1, Full-Year Sales Guidance is Optimistic
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $158.7 million. The company’s... 
Via StockStory
iRhythm Earnings: What To Look For From IRTC
Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be reporting results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
3 Reasons IRTC is Risky and 1 Stock to Buy Instead
iRhythm has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78.8%, reaching $102.62 per share. This was partly thanks to its solid quarterly results, and the... 
Via StockStory
Topics Bankruptcy
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
1 Small-Cap Stock Worth Your Attention and 2 to Question
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 Healthcare Stocks in the Doghouse
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried
The company is facing a regulatory setback. But one analyst doesn't expect that to impact its upcoming, potential approval. 
Via Investor's Business Daily
1 Growth Stock to Target This Week and 2 to Ignore
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.